KOREA WHO
-
-
-
CEO of Intocell
Park Tae-kyo
Chemist-Turned Biotech Founder Faces Patent Risk Crisis
-
Last Updated on Oct 3, 2025
-
CEO of Intocell
Life Summary
Park Tae-kyo is the CEO of IntoCell.
He was born on February 12, 1960.
He graduated from the Department of Chemistry at Seoul National University and earned his Ph.D. in Chemistry from the Massachusetts Institute of Technology (MIT).
After completing postdoctoral research at Yale University and the Memorial Sloan Kettering Cancer Center in New York, he worked as a senior researcher at LG Life Sciences’ Technology Research Institute.
In 2006, he co-founded LegoChem Biosciences (now LigaChem Biosciences), where he served as Senior Executive Vice President and Chief Technology Officer (CTO).
He declined the CEO position at LigaChem to focus on the development of antibody-drug conjugate (ADC) platforms and founded IntoCell in 2015.
He is a rare example of a chemist-turned-entrepreneur in the pharmaceutical and biotechnology industry.
He devised “ConjuALL,” the core platform technology of LegoChem Biosciences.
Less than two months after IntoCell’s KOSDAQ listing, the company faced criticism over the termination of a technology transfer agreement, raising questions about its technology commercialization capability. The company also faces challenges in managing patent risks.
#IntoCell #ParkTaeKyo #biotech #ADC #ConjuALL #LigaChem #pharmaceutical #KOSDAQ #MIT #chemistry
He was born on February 12, 1960.
He graduated from the Department of Chemistry at Seoul National University and earned his Ph.D. in Chemistry from the Massachusetts Institute of Technology (MIT).
After completing postdoctoral research at Yale University and the Memorial Sloan Kettering Cancer Center in New York, he worked as a senior researcher at LG Life Sciences’ Technology Research Institute.
In 2006, he co-founded LegoChem Biosciences (now LigaChem Biosciences), where he served as Senior Executive Vice President and Chief Technology Officer (CTO).
He declined the CEO position at LigaChem to focus on the development of antibody-drug conjugate (ADC) platforms and founded IntoCell in 2015.
He is a rare example of a chemist-turned-entrepreneur in the pharmaceutical and biotechnology industry.
He devised “ConjuALL,” the core platform technology of LegoChem Biosciences.
Less than two months after IntoCell’s KOSDAQ listing, the company faced criticism over the termination of a technology transfer agreement, raising questions about its technology commercialization capability. The company also faces challenges in managing patent risks.
#IntoCell #ParkTaeKyo #biotech #ADC #ConjuALL #LigaChem #pharmaceutical #KOSDAQ #MIT #chemistry